Moon Sun Jae, Lee Weon-Young, Hwang Jin Seub, Hong Yeon Pyo, Morisky Donald E
Department of Preventive Medicine, College of Medicine, Chung-Ang University, Seoul, Republic of Korea.
Department of Computer science and Statistics, Daegu University, Gyeongsan-si, Gyeongsangbuk-do, Republic of Korea.
PLoS One. 2017 Nov 2;12(11):e0187139. doi: 10.1371/journal.pone.0187139. eCollection 2017.
This systematic review examined the reliability and validity of the Morisky Medication Adherence Scale-8 (MMAS-8), which has been widely used to assess patient medication adherence in clinical research and medical practice.
Of 418 studies identified through searching 4 electronic databases, we finally analyzed 28 studies meeting the selection criteria of this study regarding the reliability and validity of MMAS-8 including sensitivity and specificity. Meta-analysis for Cronbach's α, intraclass correlation coefficient (ICC), sensitivity and specificity to detect a patient with nonadherence to medication were performed. The pooled estimates for Cronbach's α and ICC were calculated using the random-effects weighted T transformation. A bivariate random-effects model was used to estimate pooled sensitivity and specificity.
The pooled Cronbach's α estimate for type 2 diabetes group in 7 studies and osteoporosis group in 3 studies were 0.67 (95% Confidence Interval(CI), 0.65 to 0.69) and 0.77 (95% CI, 0.72 to 0.83), respectively. With regard to test-retest, the pooled ICC for type 2 diabetes group in 3 studies and osteoporosis group in 2 studies were 0.81 (95% CI, 0.75 to 0.85) and 0.80 (95% CI, 0.74 to 0.85). For a cut-off value of 6, the pooled sensitivity and specificity in 12 studies were 0.43 (95% CI, 0.33 to 0.53) and 0.73 (95% CI, 0.68 to 0.78), respectively.
The MMAS-8 had acceptable internal consistency and reproducibility in a few diseases like type 2 diabetes. Using the cut-off value of 6, criterion validity was not enough good to validly screen a patient with nonadherence to medication. However, this study did not calculated a pooled estimate for criterion validity using the higher values than 6 as a cut-off value since most of included individual studies did not report criterion validity based on those values.
本系统评价考察了Morisky药物依从性量表8(MMAS-8)的信度和效度,该量表在临床研究和医疗实践中被广泛用于评估患者的药物依从性。
通过检索4个电子数据库共识别出418项研究,最终分析了28项符合本研究关于MMAS-8信度和效度(包括敏感性和特异性)选择标准的研究。对Cronbach's α、组内相关系数(ICC)、检测未坚持服药患者的敏感性和特异性进行了Meta分析。使用随机效应加权T变换计算Cronbach's α和ICC的合并估计值。采用双变量随机效应模型估计合并敏感性和特异性。
7项研究中2型糖尿病组和3项研究中骨质疏松组的Cronbach's α合并估计值分别为0.67(95%置信区间(CI),0.65至0.69)和0.77(95%CI,0.72至0.83)。关于重测,3项研究中2型糖尿病组和2项研究中骨质疏松组的ICC合并值分别为0.81(95%CI,0.75至0.85)和0.80(95%CI,0.74至0.85)。对于截断值为6,12项研究中的合并敏感性和特异性分别为0.43(95%CI,0.33至0.53)和0.73(95%CI,0.68至0.78)。
MMAS-8在2型糖尿病等少数疾病中具有可接受的内部一致性和可重复性。使用截断值6时,效标效度不足以有效筛查未坚持服药的患者。然而,由于大多数纳入的个体研究未报告基于高于6的值作为截断值的效标效度,本研究未计算该效标效度的合并估计值。